TTrialPathMatch Me to Trials
← Back to trials
RecruitingHepatocellular Carcinoma (HCC)Cholangiocarcinoma

Collection of Blood and Tissue Samples From Patients With Primary Liver Cancer.

Eligible age

18–90 yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The project aims to collect blood, tissue samples, and clinical data from patients with primary liver cancer (mainly hepatocellular carcinoma and intrahepatic cholangiocarcinoma) undergoing systemic therapy, surgical resection, or liver biopsy. Primary liver cancer is a growing global health challenge, with over one million cases expected by 2025 and a lack of effective treatments. The three-year study will systematically collect and store samples to support translational research for new therapies. Blood will be drawn at key points during systemic therapy, while tissue samples will be obtained from surgical resections or biopsies, provided they are not needed for diagnostics.

Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia

You may qualify if…

  • Primary liver cancer (hepatocellular carcinoma or intrahepatic cholangiocarcinoma)
  • Signed informed consent
  • Patient eligible to start first-line systemic therapy
  • Patient eligible for surgical resection

You may not qualify if…

  • Concurrent conditions with a life expectancy of less than 12 months
  • Autoimmune or chronic inflammatory diseases
  • Substance abuse dependency
  • Other active extrahepatic malignancies or those treated within the last 3 years, except for the following exceptions:
  • Tumors resected with curative intent and with no evidence of disease recurrence for \>3 years prior to signing the informed consent, considered at low risk of recurrence
  • Adequately resected non-melanoma skin cancers or lentigo maligna with no evidence of metastasis
  • Adequately treated carcinoma in situ of the cervix with no evidence of recurrence
  • Prostatic intraepithelial neoplasia with no evidence of infiltrative disease

Source: ClinicalTrials.gov · NCT06899854 · last updated 2025-04-03